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A B S T R A C T
Stock solutions of telithromycin, ABT-773, azith-
romycin, clarithromycin, erythromycin, roxithro-
mycin and dirithromycin were each prepared
with eight different combinations of solvents and
diluents. Broth microdilution trays were then
prepared and frozen at ) 60 C. Standard quality
control strains were evaluated periodically during
a 12-week storage time. There were no significant
changes in MICs with different solvents and
diluents. It was concluded that the easiest
approach was to dissolve each compound in
water with a small volume (< 2.5 lL ⁄mL) of
glacial acetic acid added in a dropwise fashion,
followed by further dilutions in deionised water.
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Committee for Clinical Laboratory Standards
(NCCLS) has issued a table specifying the solvent
and diluent to be used for preparing stock
solutions of antimicrobial agents [1]. For macro-
lide, azalide and ketolide compounds, the solvent
is either ethanol or methanol, and the diluent is
either water, a phosphate buffer, or a nutrient
broth. The macrolides occasionally require a fairly
large volume of alcohol in order to keep the drug
in solution, which can affect the ability of stock
solutions to be frozen for long-term storage. The
potentially toxic solvent dimethylsulphoxide is an
alternative solvent that might be considered.
In the search for a more reliable method for
dissolving and diluting macrolide and ketolide
compounds, it was found that they would dis-
solve in water after addition of a very small
amount of glacial acetic acid. A series of experi-
ments was then performed to determine whether
this method would affect the end result of
microdilution tests and, specifically, whether
quality control guidelines would need to be
changed if a new solvent or diluent was used.
Seven different compounds were studied:
telithromycin, ABT-773, azithromycin, clarith-
romycin, erythromycin, roxithromycin, and
dirithromycin (provided by their respective man-
ufacturers). Stock solutions were prepared with
four different solvents: ethanol, methanol,
dimethylsulphoxide, or acetic acid. In each case,
the solvent was added slowly until a clear
solution was achieved, which was then further
diluted with either water, a phosphate buffer, or
Mueller–Hinton broth (Table 1). For dissolving
with acetic acid, the compound was added to a
small volume of water (half the total volume
needed), and glacial acetic acid was then added
dropwise until the material dissolved completely.
This took < 2.5 lL of acetic acid ⁄mL. The solution
was then further diluted with deionised water.
Working solutions were prepared to con-
tain 320 mg ⁄L or (for Haemophilus influenzae)
1280 mg ⁄L. Subsequent dilutions were prepared
with the broth medium appropriate for the
species being tested: cation-adjusted Mueller–
Hinton broth (CAMHB) for Staphylococcus aureus
ATCC 29213; CAMHB with lysed horse blood
2–3% v ⁄ v for Streptococcus pneumoniae ATCC
49619; and Haemophilus Test Medium (HTM)
for H. influenzae ATCC 49247. The range of
concentrations in each microdilution panel was
varied for each control strain in order to ensure
on-scale endpoints throughout the study. When
the Gram-positive control strains were tested, the
working solutions were further diluted in CAM-
HB to provide 16 mg ⁄L and 1.0 mg ⁄L, and these
were then serially diluted to provide 12 doubling
concentrations. For testing the H. influenzae con-
trol strain, the working solutions were diluted
1 : 5 in HTM broth to provide an initial concen-
tration of 256 mg ⁄L (64 mg ⁄L for azithromycin or
telithromycin). Serial dilutions were then pre-
pared in HTM broth and dispensed into wells in
microdilution trays. On the day of preparation,
the appropriate control strain was tested in
triplicate, using the methods defined by the
NCCLS [1]. The remaining trays were stored at
) 60 C, and triplicate tests were repeated every
3 weeks for a total of 12 weeks. Broth from
uninoculated microdilution panels was aspirated
from wells containing the highest and lowest
concentrations tested, and the pH of each was
recorded. These pH values were compared with
the pH of broth in the growth control well
without antibiotics.
Table 1 shows the median of 15 MIC values
obtained in each solution. In all cases, the 15 MICs
were no more than one doubling concentration
from the median value. Median MICs from panels
prepared with different types of working solution
were essentially the same (± 1 doubling concen-
tration) for each of the seven study agents. The
solvent and diluent did not appear to influence
the final result with quality control strains.
Table 2 shows the overall range of all 120 MICs
recorded for each control strain. This range of
observed MICs is contrasted with the quality
control ranges that have been defined in NCCLS
documents [1,2]. Since roxithromycin and ABT-
773 are not included in the NCCLS tables, control
limits were those proposed elsewhere [3] (data on
file). Only ten of the 3024 MIC values were outside
the quality control ranges, and none of those
involved solutions prepared with acetic acid.
The pH values in test wells prepared in
CAMHB were essentially the same (± 0.1 unit)
as that of the control broth without antibiotic.
However, when trays were prepared with HTM
broth, the working solutions were diluted only
1 : 5 to provide 256 mg ⁄L or 1 : 20 for 64 mg ⁄L
(telithromycin and azithromycin). Wells prepared
to contain 256 mg ⁄L contained enough solvent
or diluent to lower the pH by approximately
0.2 units, especially when acetic acid was the
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Table 1. Performance of two keto-
lides, an azalide and four macrolides
when microdilution panels were
prepared with eight different types
of working solution of each antimi-
crobial agent
Antimicrobial agent,
stock solution solventsa and
working solution diluentsb
Median of 15 MICs (mg ⁄L)c
Streptococcus
pneumoniae
ATCC 49619
Staphylococcus
aureus
ATCC 29213
Haemophilus
influenzae
ATCC 49247
Telithromycin
Ethanol (9% v ⁄ v) in pH 7.2 buffer
Water diluent 0.008 0.12 2.0
Buffer diluent 0.008 0.12 1.0
Methanol (9% v ⁄ v) in pH 7.2 buffer
Water diluent 0.016 0.12 2.0
Buffer diluent 0.016 0.12 1.0
Acetic acid (2.5 lL ⁄mL) in water
Water diluent 0.008 0.06 1.0
Buffer diluent 0.008 0.06 2.0
DMSOd (9% v ⁄ v) in pH 7.2 buffer
Water diluent 0.008 0.06 1.0
Buffer diluent 0.008 0.06 2.0
ABT-773
Ethanol (9% v ⁄ v) in pH 6.5 buffer
Water diluent 0.016 0.06 2.0
Buffer diluent 0.016 0.06 2.0
Methanol (9% v ⁄ v) in pH 6.5 buffer
Water diluent 0.016 0.06 2.0
Buffer diluent 0.008 0.06 2.0
Acetic acid (2.0 lL ⁄mL) in water
Water diluent 0.016 0.12 2.0
Buffer diluent 0.016 0.12 2.0
DMSO (13% v ⁄ v) in pH 6.5 buffer
Water diluent 0.016 0.12 2.0
Buffer diluent 0.016 0.06 2.0
Azithromycin
Ethanol (6% v ⁄ v) in CAMHB
CAMHB diluent 0.12 1.0 1.0
Buffer diluent 0.12 1.0 1.0
Methanol (6% v ⁄ v) in CAMHB
CAMHB diluent 0.12 2.0 2.0
Buffer diluent 0.12 2.0 2.0
Acetic acid (1.8 lL ⁄mL) in water
Water diluent 0.12 1.0 2.0
Buffer diluent 0.12 1.0 2.0
DMSO (6% v ⁄ v) in CAMHB
CAMHB diluent 0.12 1.0 2.0
Buffer diluent 0.12 1.0 2.0
Clarithromycin
Ethanol (40% v ⁄ v) in pH 6.5 buffer
Water diluent 0.03 0.5 8.0
Buffer diluent 0.03 0.5 8.0
Methanol (42% v ⁄ v) in pH 6.5 buffer
Water diluent 0.03 0.5 8.0
Buffer diluent 0.03 0.5 8.0
Acetic acid (1.2 lL ⁄mL) in water
Water diluent 0.03 0.25 4.0
Buffer diluent 0.03 0.25 4.0
DMSO (20% v ⁄ v) in pH 6.5 buffere
Water diluent 0.03 0.5 8.0
Buffer diluent 0.03 0.5 NDf
Erythromycin
Ethanol (10% v ⁄ v) in water
Water diluent 0.06 0.5 4.0
Buffer diluent 0.06 0.5 4.0
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Table 1. continued
Antimicrobial agent,
stock solution solventsa and
working solution diluentsb
Median of 15 MICs (mg ⁄L)c
Streptococcus
pneumoniae
ATCC 49619
Staphylococcus
aureus
ATCC 29213
Haemophilus
influenzae
ATCC 49247
Methanol (10% v ⁄ v) in water
Water diluent 0.06 0.5 8.0
Buffer diluent 0.06 0.5 8.0
Acetic acid (1.2 lL ⁄mL) in water
Water diluent 0.06 1.0 8.0
Buffer diluent 0.06 0.5 8.0
DMSO (10% v ⁄ v) in water
Water diluent 0.06 0.5 4.0
Buffer diluent 0.06 0.5 4.0
Roxithromycin
Ethanol (10% v ⁄ v) in water
Water diluent 0.12 1.0 8.0
Buffer diluent 0.12 1.0 16
Methanol (11% v ⁄ v) in water
Water diluent 0.12 1.0 8.0
Buffer diluent 0.12 1.0 16
Acetic acid (1.3 lL ⁄mL) in water
Water diluent 0.12 1.0 8.0
Buffer diluent 0.12 1.0 8.0
DMSO (50% v ⁄ v) in watere
Water diluent 0.12 1.0 16
Buffer diluent 0.06 1.0 NDf
Dirithromycin
Ethanol (5% v ⁄ v) in water
Water diluent 0.12 2.0 16
Buffer diluent 0.12 2.0 16
Methanol (5% v ⁄ v) in water
Water diluent 0.12 2.0 16
Buffer diluent 0.12 2.0 16
Acetic acid (2.5 lL ⁄mL) in water
Water diluent 0.12 2.0 16
Buffer diluent 0.12 2.0 16
DMSO (15% v ⁄ v) in watere
Water diluent 0.25 4.0 16
Buffer diluent 0.25 4.0 NDf
aStock solutions with 2560 mg ⁄L were prepared by dissolving antibiotic powder
in a minimal volume of solvent and then adjusting by adding the diluent
recommended by the manufacturer of each agent.
bWorking solutions with 320 mg ⁄L (1280 mg ⁄L when testing H. influenzae) were
prepared by diluting each stock solution with deionised water and with a pH 7.2
phosphate buffer.
cSerial dilutions of each working solution were prepared by diluting in cation-
adjusted Mueller–Hinton broth (CAMBH) with or without lysed horse blood or
in Haemophilus Test Medium (HTM broth), and microdilution test panels were
prepared and stored at ) 70 C until needed. Each control strain was tested in
triplicate every 3 weeks to document short-term stability (12 weeks at ) 70 C).
There was no consistent trend for a change in MICs during storage, and all 15
MICs differed by no more than one doubling concentration from the median.
dDMSO, dimethylsulphoxide (potentially toxic solvent).
eClarithromycin, roxithromycin and dirithromycin were not very soluble in
DMSO, and thus the stock solution contained only 1280 mg ⁄L.
fND, not done; because of the limited solubility of two macrolides in DMSO, only
one working solution was evaluated in final concentrations great enough to
obtain on-scale endpoints with the H. influenzae control strain.
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solvent. The pH values of lower concentrations
did not differ from that of the control. When a
20-fold dilution was prepared to achieve an initial
concentration of 64 mg ⁄L, the pH values of all
eight preparations were essentially identical to
that of the broth control. The slight decrease in pH
involved only extremely high concentrations of
the study compounds and was well above the
range of MICs expected for the quality control
strains. However, it was concluded that working
solutions should contain enough drug to require a
1 : 10 or 1 : 20 dilution with a broth medium
before serial dilutions are carried out.
To further evaluate the effect of diluents carried
over in the first well, a set of ten strains was
selected with elevated macrolide MICs (six
S. pneumoniae, three Streptococcus pyogenes, and
one Staph. aureus). Susceptibility tests were per-
formed with the different types of working
solutions defined by the NCCLS [1,2] and with a
weak solution of acetic acid diluted in water or in
a phosphate buffer. MICs recorded for this
challenge set of resistant strains were not affected
by the solvent or diluent. MICs of all seven drugs
were essentially the same, even when they were
> 256 mg ⁄L (data not shown).
As ethanol, methanol and dimethylsulphoxide
are not entirely satisfactory solvents for the
macrolides, it was concluded that a dilute solu-
tion of glacial acetic acid is the preferred solvent
for all seven study drugs. To prepare a stock
solution, the compound should be added to
deionised water (approximately half the total
volume desired) and the glacial acetic acid then
added in a dropwise fashion until the compound
is completely dissolved (this should require
< 2.5 lL ⁄mL). Further dilution can then be
carried out with deionised water. The working
solution should contain at least 10–20-fold more
antibiotic than the highest concentration that will
be tested. This procedure has been recognised by
the NCCLS subcommittee on susceptibility test-
Table 2. Overall range of MICs des-
cribed in Table 1 compared to qual-
ity control limits anticipated for each
of three control strains
Antimicrobial agent
and MIC ranges
MIC (mg ⁄L) ranges and quality control limits
Streptococcus
pneumoniae
ATCC 49619
Staphylococcus
aureus
ATCC 29213
Haemophilus
influenzae
ATCC 49247
Telithromycin
Overall range of 120 MICs 0.004–0.016 0.06–0.12 1.0–2.0
Quality control limits 0.004–0.03 0.06–0.25 1.0–4.0
ABT-773
Overall range of 120 MICs 0.008–0.03a 0.06–0.12 1.0–2.0
Quality control limits 0.002–0.016 0.06–0.25 1.0–4.0
Azithromycin
Overall range of 120 MICs 0.06–0.25 1.0–4.0b 1.0–4.0
Quality control limits None 0.5–2.0 1.0–4.0
Clarithromycin
Overall range of 120 MICs 0.03–0.03 0.25–0.5 4.0–8.0d
Quality control limits 0.03–0.12 0.12–0.5 4.0–16
Erythromycin
Overall range of 120 MICs 0.03–0.06 0.5–1.0 2.0–16
Quality control limits 0.03–0.25 0.25–1.0 None
Roxithromycin
Overall range of 120 MICs 0.06–0.12 1.0–2.0 8.0–16d
Quality control limits 0.06–0.25 0.5–2.0 8.0–32
Dirithromycin
Overall range of 120 MICs 0.06–0.25 2.0–8.0c 16–32d
Quality control limits 0.06–0.25 1.0–4.0 8.0–32
aOne of 144 MICs was outside the quality control range (stock dissolved in
ethanol).
bTwo of 144 MICs were outside the quality control range (stock dissolved in
methanol).
cSeven of 144 MICs were outside the quality control range (stock dissolved in
dimethylsulphoxide).
dOnly 75 MICs were available for analysis, because three drugs were not tested
with a buffer diluent.
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ing and is acknowledged as an accepted alter-
native approach for preparing stock solutions of
four study drugs. Solvents for ABT-773, dirithro-
mycin and roxithromycin have not yet been
presented to the subcommittee for inclusion in
this document.
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